'Preclinical data' diaporamas de présentation

RAC protocol 0307-594 PI: Michael A. Mont, MD Sponsor: TissueGene, Inc. (TherImmune Research Corp., regulatory agent) Ad

RAC protocol 0307-594 PI: Michael A. Mont, MD Sponsor: TissueGene, Inc. (TherImmune Research Corp., regulatory agent) Ad hoc Reviewer: Robert H. Carter, M.D. Summary statement. This protocol addresses a major clinical need - the ability to restore cartilage to damaged joints.

474 views • 41 slides

Clinical perspective on pharmacogenetic labeling

Clinical perspective on pharmacogenetic labeling. Some drugs have such a wide therapeutic range that individualizing the dose is not important. Predicated upon the assumption that getting the right dose of the drug for this disease is important.

418 views • 32 slides

Clinical requirement for biosimilar Products

Clinical requirement for biosimilar Products. National Organization for Research & Control of Biological products Dr. Heba Khalil, Head of Marketing Authorization & Clinical Trials Evaluation Departments. What are Biosimilars?.

358 views • 22 slides

312 views • 20 slides

511 views • 19 slides

SWEDISH-AMERICAN LIFE SCIENCE SUMMIT August 19-21, 2009

488 views • 19 slides

ANTI-CYTOKINE THERAPY

ANTI-CYTOKINE THERAPY. TNF IN RA. INCREASED IN SYNOVIAL FLUID PRODUCED BY SYNOVIOCYTES/MACROPHAGE STIMULATES IL-1, IL-6 PRODUCTION STIMULATES MMP PRODUCTION INFLAMMATORY MEDIATOR AND FATIGUE. TNF INHIBITORS IN RA. PRECLINICAL DATA TRANSGENIC MODELS ANIMAL MODELS

726 views • 15 slides